Chemicals supplier Clariant has bought a stake of undisclosed size in Haelixa, a Switzerland-based supplier of DNA tracers for industrial purposes spun out from ETH Zurich. The transaction is part of a cooperation agreement under which Clariant will support Haelixa’s product development. Founded in 2016, Haelixa supplies tracers composed of DNA sequences held inside invisible particles that are mixed into fluids and objects to give them a distinct watermark for identification purposes. The company’s services predominantly fulfil industrial needs such as oil reservoir monitoring, product tracking and the identification of leaks. Clariant believes the purchase exemplifies its endeavour of harnessing open innovation emerging from external partners including universities to complement its internal R&D programs. Haelixa was co-founded by two ETH Zurich PhD graduates –chief executive Michela Puddu, who studied chemical engineering, and chief technology officer Gediminas Mikutis, who completed his post-doctorate in chemical engineering. Richard Haldimann, head of new business development at Clariant, said: “Haelixa’s technology shows great promise in several product categories and applications which are relevant to Clariant. “We are therefore delighted to work with Haelixa and are committed to further developing and commercialising this exciting technology.”
Clariant identifies Haelixa for stake purchase
Sep 4, 2018 •
LEADERSHIP SOCIETY
Informing, connecting, and transforming the global corporate venture capital ecosystem.The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.
More featured content
Halo has researchers on speed dial for corporates
Halo has researchers on speed dial for corporates
How does a corporate find the right university researcher or startup when it's trying to solve a critical problem? Halo has the answer.
How Basel supercharged its spinout rate
How Basel supercharged its spinout rate
Basel has quietly built a life sciences ecosystem that’s becoming hard to ignore.
Crumbling system, fragile lives: can spinouts help in the senior care crisis?
Crumbling system, fragile lives: can spinouts help in the senior care crisis?
From a chest-worn device to help with Parkinson's symptoms to stress measuring socks — here are the spinouts providing support for senior citizens.
Events
Webinar: Innovate to heal - What does the hospital of the future look like?
Apr 10, 2024
Online
Online
Events
GCV Institute: Landing the Value of Corporate Venturing
May 6 -
May 9, 2024
Online
May 9, 2024
Online
Events
GCV Institute: CVC Investment Programs
May 21 -
May 22, 2024
Online
May 22, 2024
Online
Events
GCV Symposium 2024
Jun 24 -
Jun 26, 2024
London (UK)
Jun 26, 2024
London (UK)
Events
Corporate Venture in Brasil 2024 – International Delegation to Brazil
Oct 28 -
Oct 30, 2024
São Paulo (Brazil)
Oct 30, 2024
São Paulo (Brazil)
Top News
test reg